230 related articles for article (PubMed ID: 37059646)
1. Advances in treatments of patients with classical and emergent neurological toxicities of anticancer agents.
Bompaire F; Birzu C; Bihan K; Desestret V; Fargeot G; Farina A; Joubert B; Leclercq D; Nichelli L; Picca A; Tafani C; Weiss N; Psimaras D; Ricard D
Rev Neurol (Paris); 2023 Jun; 179(5):405-416. PubMed ID: 37059646
[TBL] [Abstract][Full Text] [Related]
2. Neurologic Toxicities of Immunotherapy.
Harrison RA; Majd NK; Tummala S; de Groot JF
Adv Exp Med Biol; 2021; 1342():417-429. PubMed ID: 34972978
[TBL] [Abstract][Full Text] [Related]
3. Neurological toxicities associated with immune-checkpoint inhibitors.
Touat M; Talmasov D; Ricard D; Psimaras D
Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
5. Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice.
Berzero G; Picca A; Psimaras D
Curr Opin Oncol; 2020 Nov; 32(6):603-612. PubMed ID: 32852312
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system injury from novel cancer immunotherapies.
Winter SF; Vaios EJ; Dietrich J
Curr Opin Neurol; 2020 Dec; 33(6):723-735. PubMed ID: 32941192
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
Gu T; Hu K; Si X; Hu Y; Huang H
WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
[TBL] [Abstract][Full Text] [Related]
8. Anticancer Drugs and the Nervous System.
Santomasso BD
Continuum (Minneap Minn); 2020 Jun; 26(3):732-764. PubMed ID: 32487905
[TBL] [Abstract][Full Text] [Related]
9. Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy.
Perrinjaquet C; Desbaillets N; Hottinger AF
Curr Opin Neurol; 2019 Jun; 32(3):500-510. PubMed ID: 30893101
[TBL] [Abstract][Full Text] [Related]
10. CAR-T and checkpoint inhibitors: toxicities and antidotes in the emergency department.
Lipe DN; Shafer S
Clin Toxicol (Phila); 2021 May; 59(5):376-385. PubMed ID: 33576256
[TBL] [Abstract][Full Text] [Related]
11. Neurologic Toxicities of Cancer Immunotherapies: a Review.
Harrison RA; Tummala S; de Groot J
Curr Neurol Neurosci Rep; 2020 Jun; 20(7):27. PubMed ID: 32514633
[TBL] [Abstract][Full Text] [Related]
12. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
13. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.
Morris EC; Neelapu SS; Giavridis T; Sadelain M
Nat Rev Immunol; 2022 Feb; 22(2):85-96. PubMed ID: 34002066
[TBL] [Abstract][Full Text] [Related]
14. Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
Vilaseca A; Farina A; Villagrán-García M; Pegat A; Benaiteau M; Ciano-Petersen NL; Do LD; Rogemond V; Gonçalves D; Psimaras D; Birzu C; Honnorat J; Joubert B
J Neurol; 2024 Jun; 271(6):3279-3290. PubMed ID: 38467790
[TBL] [Abstract][Full Text] [Related]
15. The role of neurologists in the era of cancer immunotherapy: Focus on CAR T-cell therapy and immune checkpoint inhibitors.
Pensato U; Guarino M; Muccioli L
Front Neurol; 2022; 13():936141. PubMed ID: 35928132
[TBL] [Abstract][Full Text] [Related]
16. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
Diamanti L; Picca A; Bini P; Gastaldi M; Alfonsi E; Pichiecchio A; Rota E; Rudà R; Bruno F; Villani V; Galiè E; Vogrig A; Valente M; Zoccarato M; Poretto V; Giometto B; Cimminiello C; Del Vecchio M; Marchioni E
Neurol Sci; 2022 Mar; 43(3):2031-2041. PubMed ID: 34424427
[TBL] [Abstract][Full Text] [Related]
17. Toxicities following CAR-T therapy for hematological malignancies.
Hernani R; Benzaquén A; Solano C
Cancer Treat Rev; 2022 Dec; 111():102479. PubMed ID: 36308910
[TBL] [Abstract][Full Text] [Related]
18. Neuromuscular complications of immune checkpoint inhibitors.
Psimaras D
Presse Med; 2018; 47(11-12 Pt 2):e253-e259. PubMed ID: 30413332
[TBL] [Abstract][Full Text] [Related]
19. Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill.
Suarez Montero JC; Caballero Gonzalez AC; Martín Aguilar L; Mancebo Cortés J
Med Intensiva (Engl Ed); 2022 Apr; 46(4):201-212. PubMed ID: 35216966
[TBL] [Abstract][Full Text] [Related]
20. Neurological Complications of CAR T Cell Therapy.
Landry K; Thomas AA
Curr Oncol Rep; 2020 Jul; 22(8):83. PubMed ID: 32607727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
